Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

36°
- Benton, AR (72018)
  Today
  
  Sunny. High 41F. Winds SSW at 5 to 10 mph..
  
  Tonight
  
  Clear skies. Low 27F. Winds light and variable.
  
  Updated: December 15, 2025 @ 12:10 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

4.860 -0.110 (-2.21%)

Streaming Delayed Price Updated: 1:26 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Annexon, Inc. - common stock

< Previous 1 2 3 4 Next >

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

November 14, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

November 10, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Biosciences to Participate in Upcoming September Investor Conferences

August 27, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

August 14, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

August 07, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

July 24, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

June 18, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 29, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 19, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 12, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 09, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

May 07, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

April 16, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

April 08, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

April 03, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

March 17, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

March 03, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

February 26, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

February 18, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

February 13, 2025

Data Reinforce Neuroprotective Effect of C1q Blockade with ANX007 Against Inflammation and Neuronal Damage

From Annexon Biosciences

Via GlobeNewswire

Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

January 13, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones

January 10, 2025

Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations

From Annexon Biosciences

Via GlobeNewswire

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 07, 2025

From Annexon Biosciences

Via GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

December 16, 2024

From Annexon Biosciences

Via GlobeNewswire

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

December 16, 2024

From Annexon Biosciences

Via GlobeNewswire

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

December 05, 2024

From Annexon Biosciences

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Annexon, Inc. - common stock (NQ:ANNX)

Press Releases about Annexon, Inc. - common stock

Sections

Services

Follow Us